文献速递糖尿病

胰腺炎后糖尿病患者的降糖治疗:全国性人群队列研究

Glucose-Lowering Therapy in Patients With Postpancreatitis Diabetes Mellitus: A Nationwide Population-Based Cohort Study.
PubMed 文献 · Diabetes Care · 2021-08-06

该丹麦全国性队列研究纳入2000-2018年398,456例成人新发糖尿病患者,其中5,879例(1.5%)为胰腺炎后糖尿病(PPDM)。研究发现PPDM常被误分类为2型糖尿病(44.9%),且部分患者使用磺脲类(25.2%)和肠促胰岛素类药物(18.0%)可能有害,而35.0%从未使用双胍类;PPDM患者胰岛素需求显著高于2型糖尿病(HR 3.10,95%CI 2.96-3.23)。

要点

  • PPDM占成人新发糖尿病的1.5%,但44.9%被误分类为2型糖尿病。
  • PPDM患者中25.2%使用磺脲类、18.0%使用肠促胰岛素类药物,可能潜在有害。
  • 35.0%的PPDM患者从未使用双胍类,而双胍类与生存获益相关。

核心结论

  • PPDM是成人常见的继发性糖尿病,但常被误分类并当作2型糖尿病治疗,尽管PPDM管理需要特殊考虑。

研究设计与样本

  • 丹麦全国性 population-based 队列研究,纳入2000-2018年所有成人起病糖尿病患者,分类为1型糖尿病、2型糖尿病或PPDM,比较各组降糖治疗处方模式。

主要发现

  • 在398,456例成人新发糖尿病患者中,PPDM 5,879例(1.5%),1型糖尿病9,252例(2.3%),2型糖尿病占96.2%。
  • PPDM发病率为7.9(95%CI 7.7-8.1)/10万人年,1型糖尿病为12.5(95%CI 12.2-12.7)/10万人年,发病率比0.6(95%CI 0.6-0.7),P<0.001。
  • 44.9%的PPDM患者被分类为2型糖尿病,25.2%使用磺脲类,18.0%使用肠促胰岛素类药物,35.0%从未使用双胍类。
  • 与2型糖尿病相比,PPDM患者胰岛素需求增加(HR 3.10,95%CI 2.96-3.23,P<0.001),尤其是慢性胰腺炎相关PPDM(HR 4.30,95%CI 4.01-4.56,P<0.001)。

临床怎么用

  • 临床应避免将PPDM误分类为2型糖尿病,需识别胰腺炎病史。
  • 对PPDM患者应谨慎使用磺脲类和肠促胰岛素类药物,优先考虑双胍类。
  • PPDM患者尤其是慢性胰腺炎相关者可能需要更早启动胰岛素治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Postpancreatitis diabetes mellitus (PPDM) is a type of secondary diabetes that requires special considerations for management. The main objective was to examine prescription patterns of glucose-lowering therapy among adults with PPDM compared with type 1 and type 2 diabetes. RESEARCH DESIGN AND METHODS: In a Danish nationwide population-based cohort study, we identified all individuals with adult-onset diabetes in the period 2000-2018 and categorized them as having type 1 diabetes, type 2 diabetes, or PPDM. We ascertained diabetes incidence rates, clinical and demographic characteristics, and classifications and prescription patterns of glucose-lowering therapy and compared these parameters across diabetes subgroups. RESULTS: Among 398,456 adults with new-onset diabetes, 5,879 (1.5%) had PPDM, 9,252 (2.3%) type 1 diabetes, and the remaining type 2 diabetes (96.2%). The incidence rate of PPDM was 7.9 (95% CI 7.7-8.1) per 100,000 person-years versus 12.5 (95% CI 12.2-12.7) for type 1 diabetes (incidence rate ratio 0.6 [95% CI 0.6-0.7]; P < 0.001). A sizeable proportion of patients with PPDM were classified as having type 2 diabetes (44.9%) and prescribed sulfonylureas (25.2%) and incretin-based therapies (18.0%) that can potentially be harmful in PPDM. In contrast, 35.0% of patients never received biguanides, which are associated with a survival benefit in PPDM. Increased insulin requirements were observed for patients with PPDM compared with type 2 diabetes (hazard ratio 3.10 [95% CI 2.96-3.23]; P < 0.001) in particular for PPDM associated with chronic pancreatitis (hazard ratio 4.30 [95% CI 4.01-4.56]; P < 0.001). CONCLUSIONS: PPDM is a common type of secondary diabetes in adults but is often misclassified and treated as type 2 diabetes, although PPDM requires special considerations for management.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Viggers R, Jensen MH, Laursen HVB, et al. Glucose-Lowering Therapy in Patients With Postpancreatitis Diabetes Mellitus: A Nationwide Population-Based Cohort Study. Diabetes Care. 2021. PMID: 34362812. doi:10.2337/dc21-0333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。